title: Guillain-Barré syndrome after treatment with sunitinib malate?
abstract: Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor used for treatment of renal cell carcinoma and gastrointestinal stromal tumor. We report a case of a patient who developed Guillain-Barrd syndrome after initial treatment with sunitinib, with recurrent symptoms upon reintroducing the drug. This is the first report of such an effect. The literature on chemotherapy-induced Guillain-Barri syndrome is also reviewed. Oncology providers should be aware of this rare but potentially serious possible adverse effect of sunitinib.
authors.affiliation: Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center, Madison, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Mulherin
authors.forename: Noelle K
authors.initials: NK
authors.lastname: Loconte
authors.forename: Kyle D
authors.initials: KD
authors.lastname: Holen
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D020275:Guillain-Barre Syndrome / Q000139:chemically induced*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib